Q2 2022 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
Greetings, ladies and gentlemen, and welcome to the BrainStorm Cell Therapeutics second-quarter 2022 conference call. (Operator Instructions) As a reminder, this call is being recorded.
And I would now like to introduce your host for today's conference, Mr. Tom Galassi of LifeSci Advisors. Mr. Galassi, you may begin.
Good morning, and thank you for joining us.
Before we begin the opening remarks, we would like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding BrainStorm Cell Therapeutics, and its potential future business operations performance.
Statements regarding the market potential for the treatment of neurodegenerative disorders such as ALS and MS, the sufficiency of the company's existing capital resources for continuing operations in 2022 and beyond, the safety and clinical effectiveness of the NurOwn technology platform, clinical trials of NurOwn, and related clinical development programs, and the company's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |